Byooviz (ranibizumab)

Numéro de dossier de l’APP: 22008
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
Treatment of:
• neovascular (wet) age-related macular degeneration (AMD)
• visual impairment due to diabetic macular edema (DME)
• visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
• visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
• visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Promoteur/fabricant:
Biogen Canada Inc.
Numéro de projet de l’ACMTS:
Sans objet
Lettre-contrat de l’APP:
Conclusion du processus de négociation: